NAS
SMMT icon

Nykredit A/S’s Summit Therapeutics SMMT Stock Holding History

Nykredit A/S’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$111K Buy
+7,634
New +$135K ﹤0.01% 1277

Other funds holding SMMT

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Nykredit A/S's SMMT Position: Q2 2026 in Review

Nykredit A/S opened a new position in Summit Therapeutics (SMMT) in Q2 2026: 7,634 shares worth $111K. The stake represents ﹤0.01% of the portfolio and ranks #1277 among its holdings.

155 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Nykredit A/S held 7,634 shares of Summit Therapeutics worth $111K as of Q2 2026.
  • Summit Therapeutics was a new Nykredit A/S position in Q2 2026.
  • Summit Therapeutics made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #1277 holding.
  • 155 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.